Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of pharmacogenetics to guide warfarin therapy.
Voora D, McLeod HL, Eby C, Gage BF. Voora D, et al. Among authors: eby c. Drugs Today (Barc). 2004 Mar;40(3):247-57. doi: 10.1358/dot.2004.40.3.820088. Drugs Today (Barc). 2004. PMID: 15148533
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF. Horne BD, et al. Among authors: eby cs. Thromb Haemost. 2012 Feb;107(2):232-40. doi: 10.1160/TH11-06-0388. Epub 2011 Dec 21. Thromb Haemost. 2012. PMID: 22186998 Free PMC article.
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Gage BF, et al. Among authors: eby c. Clin Pharmacol Ther. 2008 Sep;84(3):326-31. doi: 10.1038/clpt.2008.10. Epub 2008 Feb 27. Clin Pharmacol Ther. 2008. PMID: 18305455 Free PMC article.
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Voora D, et al. Among authors: eby c. Thromb Haemost. 2005 Apr;93(4):700-5. doi: 10.1160/TH04-08-0542. Thromb Haemost. 2005. PMID: 15841315
The pharmacogenetics of coumarin therapy.
Voora D, McLeod HL, Eby C, Gage BF. Voora D, et al. Among authors: eby c. Pharmacogenomics. 2005 Jul;6(5):503-13. doi: 10.2217/14622416.6.5.503. Pharmacogenomics. 2005. PMID: 16014000 Review.
Pharmacogenetics and anticoagulant therapy.
Gage BF, Eby CS. Gage BF, et al. J Thromb Thrombolysis. 2003 Aug-Oct;16(1-2):73-8. doi: 10.1023/B:THRO.0000014598.24114.62. J Thromb Thrombolysis. 2003. PMID: 14760217 Review.
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH; COAG Investigators. Kimmel SE, et al. Among authors: eby cs. N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251361 Free PMC article. Clinical Trial.
134 results